Xeris Biopharma Holdings annual revenue
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings Revenue Growth & History (XERS)
Xeris Biopharma Holdings reported $291.8M in revenue for fiscal 2025, an increase of 43.72% from the previous fiscal year.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $291.8M | $88.8M | +43.72% |
| 2024 | 2024-12-31 | $203.1M | $39.2M | +23.89% |
| 2023 | 2023-12-31 | $163.9M | $53.7M | +48.68% |
| 2022 | 2022-12-31 | $110.2M | $60.7M | +122.32% |
| 2021 | 2021-12-31 | $49.6M | $29.4M | +146.04% |
| 2020 | 2020-12-31 | $20.2M | — | — |
Xeris Biopharma Holdings quarterly revenue
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $92.1M | $20.6M | +28.74% |
| Q1 2026 | 2026-03-31 | $83.1M | $23.0M | +38.27% |
| Q4 2025 | 2025-12-31 | $85.8M | $25.7M | +42.78% |
| Q3 2025 | 2025-09-30 | $74.4M | $20.1M | +37.06% |
| Q2 2025 | 2025-06-30 | $71.5M | $23.5M | +48.84% |
| Q1 2025 | 2025-03-31 | $60.1M | $19.5M | +47.94% |
| Q4 2024 | 2024-12-31 | $60.1M | — | — |
| Q3 2024 | 2024-09-30 | $54.3M | $5.9M | +12.31% |
| Q2 2024 | 2024-06-30 | $48.1M | $10.1M | +26.46% |
| Q1 2024 | 2024-03-31 | $40.6M | — | — |
| Q3 2023 | 2023-09-30 | $48.3M | $18.6M | +62.56% |
| Q2 2023 | 2023-06-30 | $38.0M | $12.7M | +50.19% |
| Q4 2022 | 2022-12-31 | $33.3M | $11.7M | +54.39% |
| Q3 2022 | 2022-09-30 | $29.7M | $18.7M | +168.76% |
| Q2 2022 | 2022-06-30 | $25.3M | $16.4M | +184.15% |
| Q1 2022 | 2022-03-31 | $21.9M | $13.9M | +172.14% |
| Q4 2021 | 2021-12-31 | $21.6M | — | — |
| Q3 2021 | 2021-09-30 | $11.1M | $1.7M | +17.61% |
| Q2 2021 | 2021-06-30 | $8.9M | — | — |
| Q1 2021 | 2021-03-31 | $8.1M | — | — |
| Q3 2020 | 2020-09-30 | $9.4M | — | — |
Xeris Biopharma Holdings revenue growth trends
Over the last five reported fiscal years, revenue grew from $20.2M to $291.8M, a compound annual growth rate of 70.67%. Xeris Biopharma Holdings's latest reported quarter, Q2 2026, generated $92.1M in revenue, an increase of 28.74% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Xeris Biopharma Holdings source filings ↗